<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Pharmaceutical Product Guide &#187; liothyronine sodium</title>
	<atom:link href="http://www.pharmaceuticalproductguide.com/blog/tag/liothyronine-sodium/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.pharmaceuticalproductguide.com/blog</link>
	<description>A comprehensive guide to pharmaceutical products for medical professionals</description>
	<lastBuildDate>Fri, 11 Jun 2010 09:15:33 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Mylan receives approval for generic Cytomel</title>
		<link>http://www.pharmaceuticalproductguide.com/blog/2009/07/17/mylan-receives-approval-for-generic-cytomel/</link>
		<comments>http://www.pharmaceuticalproductguide.com/blog/2009/07/17/mylan-receives-approval-for-generic-cytomel/#comments</comments>
		<pubDate>Fri, 17 Jul 2009 18:30:23 +0000</pubDate>
		<dc:creator>Kimberly O'Brien</dc:creator>
				<category><![CDATA[FDA Approval]]></category>
		<category><![CDATA[Cytomel]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[liothyronine sodium]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[NDA]]></category>
		<category><![CDATA[new drug application]]></category>
		<category><![CDATA[thyroid deficiency]]></category>

		<guid isPermaLink="false">http://www.pharmaceuticalproductguide.com/blog/2009/07/17/mylan-receives-approval-for-generic-cytomel/</guid>
		<description><![CDATA[Mylan Pharmaceuticals has received approval from the FDA for its abbreviated new drug application (NDA) for liothyronine sodium tablets USP. The drug will be available in the strengths of 5mcg, 25mcg and 50mcg. Liothyronine sodium tablets are the generic version of King Pharmaceuticals&#8217;s treatment for thyroid deficiency, Cytomel. The company has started the shipping of [...]]]></description>
			<content:encoded><![CDATA[<p><img src="http://www.pharmaceuticalproductguide.com/blog/wp-content/uploads/2009/07/mylan.png" align="left" height="54" width="200" vspace="5" hspace="5" />Mylan Pharmaceuticals has received approval from the FDA for its abbreviated new drug application (NDA) for liothyronine sodium tablets USP. The drug will be available in the strengths of 5mcg, 25mcg and 50mcg. Liothyronine sodium tablets are the generic version of King Pharmaceuticals&#8217;s treatment for thyroid deficiency, Cytomel. The company has started the shipping of the product.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.pharmaceuticalproductguide.com/blog/2009/07/17/mylan-receives-approval-for-generic-cytomel/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
